SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around an upcoming token burn at 2000 watchers, anticipating it will drive up the token's value. Community members highlight the developer's active involvement and look forward to a second CEX listing on BiFinance. Despite some dips, the community remains bullish, emphasizing the project's resilience and continued growth.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

Fueled by news of biometric software deployments at international airports, BigBear.ai is trending as chatter around potential short squeeze and new contracts intensifies. The community draws $PLTR comparisons and anticipates a breakout, while highlighting the company&#39;s AI-driven security solutions. Bullish sentiment focuses on chart setups and the potential for significant gains.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

The $BYTE.X community is rallying around this self-proclaimed 'chosen one' meme coin, touting it as the 'future of AI'. Discussion centers on its strong community, potential for high growth, and association with the AI narrative, specifically as an 'AI dog' token.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates upcoming news and partnerships, fueled by a teaser video hinting at NBA/NHL integrations. Discussions revolve around Zebec's potential in sports betting and its positioning for mainstream adoption through regulatory compliance. Community members are actively accumulating and staking ZBCN, drawing comparisons to other successful cryptos and speculating on future exchange listings.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending as the community discusses the company's solid-state battery technology and its potential impact on the EV sector. Recent buzz surrounds the company's presence at IAA and excitement around potential partnerships, particularly with major automakers like Volkswagen, Porsche, and Audi. Bullish sentiment is fueled by speculation of upcoming news and the anticipation of the stock breaking through resistance levels.

Swell

SWELL.X is trending as the community anticipates a pump, citing its low market cap and potential for high gains, drawing comparisons to other recently successful tokens. Traders are actively discussing strategies to increase volume and push the price towards targets like 25 cents, while emphasizing its listing on Coinbase. Some users highlight its utility and staking options, suggesting it's undervalued compared to other crypto assets.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending after news that its Black Widow drone system has been approved for the NATO Support and Procurement Agency catalogue, potentially opening doors to increased sales within NATO member countries; the community is discussing the significance of this approval, revenue projections, and potential short squeezes, while also comparing RCAT to sector peers. Some are also pointing out the potential for a stock offering after the recent surge.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to excitement surrounding its potential role in powering AI data centers with clean nuclear energy, fueled by a recent analyst upgrade and a new fuel recycling facility announcement. The community is actively debating the company's high valuation relative to its pre-revenue status, with some seeing significant long-term growth potential and others warning of speculative risks and an impending correction. Discussions also involve comparisons to other nuclear energy companies and the broader implications of increased uranium consumption.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are currently driven by politically charged discussions and community perspectives are sharply divided. Much of the chatter revolves around reactions to Charlie Kirk's death and accusations of extremism, while broader market context includes Trump's policies and their potential impacts.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market continues its rally, with community members debating whether the Fed's upcoming rate decision will fuel further gains or trigger a "sell the news" event.  Bullish sentiment is fueled by hopes for rate cuts and potential deals, while bears point to overbought conditions and stretched valuations. Discussions include the influence of AI and potential market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients with thalassemia, by three months.Thalassemia is a rare, inherited blood disease that affects the production of the protein hemoglobin in red blood cells. By disrupting hemoglobin production, thalassemia reduces the number of circulating red blood cells and shortens their lifespan, resulting in anemia, fatigue, and severe complications.While the FDA was initially expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat">expected</a> by December 7. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_10_30_42_AM_png_307a186918.webp" alt="AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that these are circumstances beyond the company's control.<stembedurl>https://stocktwits.com/forprofit12/message/627455227</stembedurl>A pessimistic user, however, called for selling the company's shares.<stembedurl>https://stocktwits.com/Jadek6/message/627455837</stembedurl>In the original application, the company had described the risk of hepatocellular injury with the drug. However, the firm stated on Thursday that it has submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) in response to a recent information request from the agency.The extension in date of the FDA’s decision is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios, but a result of the new REMS submission, the company said. It further termed the REMS submission a major amendment to its original application.“We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said CEO Brian Goff. &nbsp;As per Agios, approximately 6,000 adult patients are diagnosed with thalassemia in the U.S.BofA subsequently lowered its price target on Agios Pharmaceuticals to $51 from $52 while keeping a ‘Buy’ rating on the shares. The firm noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from late-stage trials supporting the application. As such, Agios remains one of the firm's top picks even with the delay, it said.Pyrukynd is already approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase (PK) deficiency is a rare, inherited disorder causing chronic hemolytic anemia in adults, where red blood cells break down too quickly due to a lack of the PK enzyme, resulting in low red blood cell count.AGIO stock is up by 6% this year but down by over 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More 

While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 

Equity

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail chatter around Agios Pharmaceuticals spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia, regardless of transfusion status.The approval was granted under the SFDA’s Breakthrough Medicines Program and is based on results from the global Energize and Energize-T Phase 3 trials.&nbsp;<a href="https://stocktwits.com/symbol/AGIO">Shares of Agios Pharmaceuticals</a> closed 3.3% higher at $36.16 on Monday, with the stock rising another 2% in after-hours trading to $36.88.Agios had partnered with NewBridge Pharmaceuticals in 2024 to support regional commercialization efforts across the Gulf Cooperation Council (GCC), including the UAE, Kuwait, Qatar, Oman, and Bahrain.However, the milestone approval came alongside new safety scrutiny in the U.S. market.&nbsp;Leerink analyst Andrew Berens noted that three newly listed deaths involving Pyrukynd appeared in the FDA’s Adverse Event Reporting System (FAERS) in July, bringing the total to four since launch.Two of the July cases were in young patients. Berens called the developments “potentially concerning” but cautioned that FAERS entries often lack key details and context.In a regulatory filing, Agios said it was aware of the report and confirmed that three of the four cases had already been submitted to the FDA through standard pharmacovigilance processes.&nbsp;Two patients involved&nbsp;were treated with Pyrukynd for pyruvate kinase deficiency under its approved U.S. indication, while one patient with sickle cell disease&nbsp;was treated through expanded access.&nbsp;The fourth case had been reported directly to the FDA, and Agios said it is currently evaluating it.The company added that, to date, the available information does not change Pyrukynd’s benefit-risk profile as represented in its U.S. prescribing information.A regulatory decision on Pyrukynd for thalassemia is due from the U.S. FDA by Sept. 7. Additional filings are under review in the UAE and European Union.On Stocktwits, retail sentiment for Agios was ‘bullish’ amid ‘extremely high’ message volume.One user acknowledged not being bullish on the stock but noted that each reported death involved patients with severe underlying conditions.&nbsp;“Two were dealing with sickle cell complications, one was 93 and already critically ill — none were stable patients simply adding Pyrukynd to an existing regimen,” the user wrote, suggesting the outcomes may not reflect typical treatment scenarios.&nbsp;<stembedurl>https://stocktwits.com/Dkll303/message/623704770</stembedurl>Another user focused on the day’s sharp intraday recovery, and said the stock had an “absolutely incredible recovery.”<stembedurl>https://stocktwits.com/yachtsandthots/message/623705222</stembedurl>Agios’ stock has risen 13.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Agios Pharmaceuticals (AGIO) spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd. (Photo credit: Getty Images)

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

Retail investors defended Agios on Stocktwits, saying reported deaths involved critically ill patients and didn’t reflect typical use. 

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?

Earnings Preview: Agios Pharmaceuticals

4 Analysts Have This To Say About Agios Pharmaceuticals

Latest Ratings for AGIO
 DateFirmActionFromTo Mar 2022Goldman SachsMaintainsSell Mar 2022HC Wainwright & Co.MaintainsBuy Feb 2022RBC CapitalMaintainsOutperform
 View More Analyst Ratings for...

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
read more...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIO Agios Pharmaceuticals Inc